ISSN: 1309 - 3843 E-ISSN: 1307 - 7384
FİZİKSEL TIP VE REHABİLİTASYON
BİLİMLERİ DERGİSİ
www.jpmrs.com
Kayıtlı İndexler


OLGU SUNUMLARI

Fibromiyalji Sendromlu Bir Hastada Duloksetine Bağlı Huzursuz Bacak Sendromu
Duloxetine-induced Restless Legs Syndrome in a Patient with Fibromyalgia Syndrome
Received Date : 22 Sep 2020
Accepted Date : 09 Dec 2020
Available Online : 05 May 2021
Doi: 10.31609/jpmrs.2020-79096 - Makale Dili: EN
J PMR Sci. 2021;24(2):183-5
ÖZET
Huzursuz bacak sendromu (HBS), dinlenme ve uyku ile kötüleşen ve ekstremiteleri hareket ettirmekle rahatlayan nahoş hislerle karakterize nörolojik bir uyku bozukluğudur. Burada fibromiyalji sendromu tanısı alan 47 yaşında bir kadın hastaya, 30 mg duloksetin verildi. Duloksetine başladıktan 4 hafta sonra, alt ekstremitelerinde rahatsızlık hissi ortaya çıktı. Duloksetin dozu düşürüldükten sonra semptomları 1 hafta içinde kademeli olarak hafifledi. Yeni nesil antidepresanlara bağlı HBS nadirdir ve literatürde, birkaç olgu sunumu ile sınırlıdır. Bildiğimiz kadarıyla bu olgu sunumu, fibromiyalji sendromunun tedavisi sırasında duloksetinin neden olduğu HBS semptomlarının ilk raporudur.
ABSTRACT
Restless legs syndrome (RLS) is a neurological sleep disorder characterized by unpleasant sensations that worsen with resting and sleep, and relieving with moving the limbs. Herein we report a 47 year-old woman diagnosed with fibromyalgia syndrome and the dose of 30 mg duloxetine was administered to her. Four weeks later from starting duloxetine, uncomfortable sensations appeared in her lower limbs. After the dose of duloxetine had been decreased, her symptoms were alleviated gradually within one week. RLS due to new generation antidepressants is rare and limited with a few case reports in the literature. To the best of our knowledge, this case report is the first report of RLS symptoms induced by duloxetine during treatment of fibromyalgia syndrome.
REFERENCES
  1. Chahine LM, Chemali ZN. Restless legs syndrome: a review. CNS Spectr. 2006;11:511-20. [Crossref]  [PubMed] 
  2. Allen RP, Picchietti DL, Garcia-Borreguero D, et al; International Restless Legs Syndrome Study Group. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria--history, rationale, description, and significance. Sleep Med. 2014;15:860-73. [Crossref]  [PubMed] 
  3. Allen RP, Bharmal M, Calloway M. Prevalence and disease burden of primary restless legs syndrome: results of a general population survey in the United States. Mov Disord. 2011;26:114-20. [Crossref]  [PubMed] 
  4. Patatanian E, Claborn MK. Drug-induced restless legs syndrome. Ann Pharmacother. 2018;52:662-72. [Crossref]  [PubMed] 
  5. Allen RP, Barker PB, Wehrl FW, et al. MRI measurement of brain iron in patients with restless legs syndrome. Neurology. 2001;56:263-5. Erratum in: Neurology. 2015;84:105. [Crossref]  [PubMed] 
  6. Allen RP, Earley CJ. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol. 2001;18:128-47. [Crossref]  [PubMed] 
  7. Klingelhoefer L, Bhattacharya K, Reichmann H. Restless legs syndrome. Clin Med (Lond). 2016;16:379-82. [Crossref]  [PubMed]  [PMC] 
  8. Lin XW, Zhang JF, Qiu MY, et al. Restless legs syndrome in end stage renal disease patients undergoing hemodialysis. BMC Neurol. 2019;19:47. [Crossref]  [PubMed]  [PMC] 
  9. Kolla BP, Mansukhani MP, Bostwick JM. The influence of antidepressants on restless legs syndrome and periodic limb movements: a systematic review. Sleep Med Rev. 2018;38:131-40. [Crossref]  [PubMed] 
  10. Nikolaou KN, Michopoulos I, Douzenis A, et al. Restless legs syndrome associated with the combined use of duloxetine plus paroxetine. J Clin Psychopharmacol. 2015;35:345-6. [Crossref]  [PubMed] 
  11. Belli H, Akbudak M, Ural C. Duloxetine-related galactorrhea and restless legs syndrome: a case report. Psychiatr Danub. 2013;25:266-7. [PubMed] 
  12. Rottach KG, Schaner BM, Kirch MH, et al. Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res. 2008;43:70-5. [Crossref]  [PubMed] 
  13. Härmark L, van Puijenbroek E, van Grootheest K. Intensive monitoring of duloxetine: results of a web-based intensive monitoring study. Eur J Clin Pharmacol. 2013;69:209-15. [Crossref]  [PubMed]  [PMC]